Saliogen Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series B - II | Alive

Total Raised


Last Raised

$17.25M | 1 mo ago

About Saliogen Therapeutics

SalioGen, The Gene Coding Company, is advancing a new category of genetic medicine called Gene Coding. Gene Coding, a genetic modification approach, works by adding a new genomic code to turn on, off, or modify the function of new or existing genes. The Gene Coding approach is guided by an Exact DNA Integration Technology (EDIT) platform, a genome engineering technology that leverages proprietary mammal-derived enzymes we call Saliogase. With broad applicability, non-viral delivery capabilities of any size gene, and significant manufacturing advantages, EDIT has the potential to transform the treatment paradigm for inherited disorders and beyond.

Saliogen Therapeutics Headquarter Location

245 First Street 18th Floor

Cambridge, Massachusetts, 02142,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Saliogen Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Saliogen Therapeutics is included in 2 Expert Collections, including Omics.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data


Unicorns- Billion Dollar Startups

1,113 items

Latest Saliogen Therapeutics News

CF Foundation Invests in SalioGen’s Gene Coding Therapy

Jan 7, 2022

Copy article link The Cystic Fibrosis Foundation has announced an investment in SalioGen Therapeutics to support the company’s preclinical research toward  developing a new gene therapy for cystic fibrosis (CF). SalioGen is working to advance a novel type of gene therapy, called Gene Coding, which is accomplished using the company’s Exact DNA Integration Technology, or EDIT. This technology aims to insert new pieces of DNA into specific places in a cell’s genetic code, which could be exploited to turn genes on or off, or modify their function. The company’s technology takes advantage of genome engineering enzymes called Saliogase. According to SalioGen , Saliogase “seamlessly inserts new DNA of any size into precise, defined genomic locations.” Recommended Reading While SalioGen had been exploring this novel technology in other genetic diseases, the new investment will facilitate testing the approach in cystic fibrosis. CF is caused by mutations in the gene CFTR, leading to defects in the CFTR protein, which results in the abnormally thick mucus and other symptoms that characterize the disease. “SalioGen’s Gene Coding approach seeks to insert a large piece of healthy CFTR DNA at a precise location within the CFTR gene, which could enable the expression of a functional CFTR protein in essentially all individuals with CF,” Martin Mense, PhD, said in a press release . Mense is CF Foundation senior vice president of drug discovery and director of the CF Foundation Therapeutics Lab. Mense added that such an approach is expected to be effective regardless of the specific mutation(s) in the CFTR gene found in a given patient. By contrast, other therapies like CFTR modulators are effective only in people with specific mutations. The new investment is part of the CF Foundation’s “ Path to a Cure ,” a $500 million initiative that aims to speed up the development of experimental treatments that aim to address the root cause of CF — whether through gene therapies , or other methods that restore functionality of the CFTR protein. Details of the investment were not disclosed. “Genetic therapies are the key to curing CF and, while it is still very early days in this scientific quest, we’re investing in many different approaches that offer promise,” Mense said.

Saliogen Therapeutics Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Saliogen Therapeutics Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.